Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group
- PMID: 10334346
- DOI: 10.1016/s0002-9394(99)00034-3
Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group
Abstract
Purpose: To compare the safety and efficacy of loteprednol etabonate 0.5% ophthalmic suspension with prednisolone acetate 1.0% ophthalmic suspension in reducing the ocular signs and symptoms associated with acute anterior uveitis.
Methods: Two prospective studies were conducted in sequence. Both were parallel, randomized, double-masked, active-controlled comparisons conducted at academic or private practice clinics in the United States. Efficacy was evaluated by the proportion of patients with a score of 0 for key signs and symptoms of uveitis. Intraocular pressure was increased regularly. The first study involved up to 42 days of treatment, starting with a dose of eight times per day. The second study involved up to 28 days of treatment, starting with a dose of 16 times per day.
Results: In the first study (N = 70), the proportion of patients achieving resolution by the final visit was anterior chamber cell (74% loteprednol etabonate, 88% prednisolone acetate, P = .194) and flare (71% loteprednol etabonate, 81% prednisolone acetate, P = .330). In the second study (N = 175), the proportion of patients achieving resolution by the final visit was anterior chamber cell (72% loteprednol etabonate, 87% prednisolone acetate, P = .015) and flare (66% loteprednol etabonate, 82% prednisolone acetate, P = .017). In both studies, intraocular pressure increase of more than 10 mm Hg was observed more frequently in patients receiving prednisolone acetate (seven patients) than those receiving loteprednol etabonate (one patient).
Conclusions: Although a clinically meaningful reduction of signs and symptoms was noted in both treatment groups, loteprednol etabonate was less effective than prednisolone acetate in both of these controlled studies. However, the more favorable profile of loteprednol etabonate with respect to intraocular pressure increase may make it useful in many patients.
Comment in
-
New corticosteroids for the treatment of ocular inflammation.Am J Ophthalmol. 1999 May;127(5):597-9. doi: 10.1016/s0002-9394(99)00049-5. Am J Ophthalmol. 1999. PMID: 10334354 Review. No abstract available.
Similar articles
-
Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1.J Cataract Refract Surg. 1998 Nov;24(11):1480-9. doi: 10.1016/s0886-3350(98)80170-3. J Cataract Refract Surg. 1998. PMID: 9818338 Clinical Trial.
-
Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery.J Cataract Refract Surg. 2013 Feb;39(2):168-73. doi: 10.1016/j.jcrs.2012.10.039. Epub 2012 Dec 8. J Cataract Refract Surg. 2013. PMID: 23232255 Clinical Trial.
-
A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2.Ophthalmology. 1998 Sep;105(9):1780-6. doi: 10.1016/s0161-6420(98)99054-6. Ophthalmology. 1998. PMID: 9754192 Clinical Trial.
-
Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use.Int Ophthalmol. 2012 Oct;32(5):507-17. doi: 10.1007/s10792-012-9589-2. Epub 2012 Jun 16. Int Ophthalmol. 2012. PMID: 22707339 Free PMC article. Review.
-
New corticosteroids for the treatment of ocular inflammation.Am J Ophthalmol. 1999 May;127(5):597-9. doi: 10.1016/s0002-9394(99)00049-5. Am J Ophthalmol. 1999. PMID: 10334354 Review. No abstract available.
Cited by
-
Long-Term Outcome of Treatment with Topical Corticosteroids for Severe Dry Eye Associated with Sjögren's Syndrome.Chonnam Med J. 2015 Apr;51(1):26-32. doi: 10.4068/cmj.2015.51.1.26. Epub 2015 Apr 14. Chonnam Med J. 2015. PMID: 25914877 Free PMC article.
-
Use of loteprednol for routine prophylaxis after photorefractive keratectomy.Clin Ophthalmol. 2012;6:653-9. doi: 10.2147/OPTH.S30282. Epub 2012 May 1. Clin Ophthalmol. 2012. PMID: 22570546 Free PMC article.
-
Locally administered ocular corticosteroids: benefits and risks.Drug Saf. 2002;25(1):33-55. doi: 10.2165/00002018-200225010-00004. Drug Saf. 2002. PMID: 11820911 Review.
-
Topical Anti-Inflammatory Agents for Non-Infectious Uveitis: Current Treatment and Perspectives.J Inflamm Res. 2022 Nov 28;15:6439-6451. doi: 10.2147/JIR.S288294. eCollection 2022. J Inflamm Res. 2022. PMID: 36467992 Free PMC article. Review.
-
Treatment of noninfectious uveitis.Arq Bras Oftalmol. 2021 Nov-Dec;84(6):610-621. doi: 10.5935/0004-2749.20220094. Arq Bras Oftalmol. 2021. PMID: 34431877 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources